Dermapharm Holding Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Hans-Georg Feldmeier
Algemeen directeur
€1.4m
Totale compensatie
| Percentage CEO-salaris | 59.7% |
| Dienstverband CEO | 7.3yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 2.2yrs |
| Gemiddelde ambtstermijn bestuur | 7.3yrs |
Recente managementupdates
Recent updates
Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden
Sep 28
Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope
Jun 21These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively
Apr 29Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings
Feb 07Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly
Dec 15An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued
Nov 17Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
Aug 28Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price
Aug 01Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
May 29Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?
May 03Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear
Apr 04We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt
Feb 22Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Nov 17Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Aug 16Is Dermapharm Holding (ETR:DMP) A Risky Investment?
May 18Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?
Feb 17These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well
Nov 19Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Aug 21Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?
Jul 31Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?
May 03Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)
Apr 16Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly
Mar 25Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?
Mar 07Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?
Feb 15Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend
Jan 29Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Dec 24
The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More
Dec 07Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models
Nov 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | €83m |
| Mar 31 2024 | n/a | n/a | €57m |
| Dec 31 2023 | €1m | €821k | €62m |
| Sep 30 2023 | n/a | n/a | €95m |
| Jun 30 2023 | n/a | n/a | €123m |
| Mar 31 2023 | n/a | n/a | €146m |
| Dec 31 2022 | €1m | €800k | €134m |
| Sep 30 2022 | n/a | n/a | €176m |
| Jun 30 2022 | n/a | n/a | €185m |
| Mar 31 2022 | n/a | n/a | €211m |
| Dec 31 2021 | €1m | €800k | €210m |
| Sep 30 2021 | n/a | n/a | €162m |
| Jun 30 2021 | n/a | n/a | €123m |
| Mar 31 2021 | n/a | n/a | €95m |
| Dec 31 2020 | €736k | €411k | €86m |
Compensatie versus markt: De totale vergoeding ($USD 1.49M ) Hans-Georg } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.58M ).
Compensatie versus inkomsten: De vergoeding van Hans-Georg is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Hans-Georg Feldmeier
7.3yrs
Tenure
€1,375,000
Compensatie
Dr. Hans-Georg Feldmeier is the Chief Executive Officer and Chairman of the Management Board at Dermapharm Holding SE and also serves as Member of the Management Board from August 2017.
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman of the Management Board | 7.3yrs | €1.38m | geen gegevens | |
| CFO, Chief Compliance Officer & Member of Management Board | 2yrs | €617.00k | geen gegevens | |
| Chief Marketing Officer & Member of Management Board | 2.2yrs | €612.00k | geen gegevens | |
| Head of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens |
2.2yrs
Gemiddelde duur
Ervaren management: Het managementteam van DMP wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Independent Member of Supervisory Board | 6.8yrs | €80.00k | geen gegevens | |
| Chairman of the Supervisory Board | 7.3yrs | €80.00k | geen gegevens | |
| Independent Vice Chairman of the Supervisory Board | 7.3yrs | €80.00k | geen gegevens |
7.3yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DMP wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).